Boston-based Pear Therapeutics, founded by Corey McCann, made headlines in September 2017 when it received FDA clearance for its app-based therapy designed for people addicted to alcohol, cocaine, marijuana and other recreational drugs.
Pear Therapeutics then signed a deal with Novartis’ Sandoz unit in April 2018 to market its line of digital therapeutics. Later that same year, its reSET-O app was approved for use with opioid addicts in outpatient treatment programs. The companies are currently working on therapies for multiple sclerosis and schizophrenia.
Pear Therapeutics has certainly caught the eye of investors. At the start of 2019, the company announced it had closed a $64 million Series C funding led by Temasek, with participation from Novartis and others. A year earlier, the company had landed $50 million in Series B funding.
McCann was an investor with MPM Capital before founding Pear. While at McKinsey & Co., he advised health-adjacent companies on the acquisition, development and commercialization of life-science technologies.
From the May 01, 2019 Issue of MM+M - Medical Marketing and Media
